← Leaderboards
Benjamin Blass
Praeventix, Llc
$1,717,697
Attributed
$5,858,091
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,858,091 · 4
By mechanism
R44$5,276,290 · 2
R43$581,801 · 2
Top collaborators
- Daniel J Canney7 shared
- Douglas Anthony Pippin7 shared
- Ellen Ann Walker3 shared
Most similar at Praeventix, Llc
Same institution · by research overlap
- Daniel J Canney$1,809,545
- Carlos A Barrero$91,848
Others in their field
Other Emerging Leaders on “Link”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Susan M Landau · University Of California Berkeley$47,252,026
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,507,271
- Kathleen Maletic Neuzil · Emory University$25,301,215
- Anthony Philippakis · University Of California Santa Cruz$23,897,237
- Bronwen Shaw · Medical College Of Wisconsin$18,756,649
Research focus
LinkAcuteSerotoninDrug KineticsDoseBrain RegionReportingSeriesMedicalSerotonin 7 ReceptorEfficacy StudyProgramsBrainPlasmaLeadPharmaceutical PreparationsIn VivoChronicPharmacologyExhibitsPermeabilityLiteratureBinding ProteinsBiological Availability
Grant awards (7)
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1,250,000
R44 · FY2024 · DA
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$1,250,000
R44 · FY2023 · DA
In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder$320,000
R44 · FY2022 · DA
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1,228,145
R44 · FY2019 · DK
In vivo Characterization of PRA078C in the Rat Cocaine Reinstatement Model$350,000
R43 · FY2019 · DA
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$1,228,145
R44 · FY2018 · DK
Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease$231,801
R43 · FY2017 · DK